Showing 25 Results
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
- Value Assessment Frameworks
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
- Health Spending
- Health Care Quality Measures
Quality measures can help payers to reward better care, providers to take action to improve care, and patients to make informed decisions about where to seek care. Often, quality measures are focused…
There is growing recognition that improving access to care and patient health, including access to medications, requires focus on social, economic and environmental factors. At its upcoming…
To understand when and how individual treatment effects are examined, conducted and reported, this study evaluated existing multiperson N-of-1 studies, which can identify whether an intervention is…
NPC President Dan Leonard sat down for a Q&A session with Sandie Preiss, Vice President for Advocacy and Access at the Arthritis Foundation, to discuss how the value of treatments for arthritis…
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
Distributed data network drug safety analyses are difficult to interpret in the face of heterogeneity, or individual treatment effects.
The research was intended to identify the current landscape and best practice approaches for consumer-directed health plans and pharmacy benefits, as well as understand the health and economic impact…
- Health Spending
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.
- Value-Based Insurance Design
The concept of heterogeneity is explained and further explored via four articles published in the June 2014 issue of the Journal of Managed Care & Specialty Pharmacy: The Good, the Bad, and the…
Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react differently to treatments, the factors that impact treatment outcomes, including…